Zhejiang Huakang Pharmaceutical Future Growth
Future criteria checks 2/6
Zhejiang Huakang Pharmaceutical is forecast to grow revenue at 28.2% per annum.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
Food earnings growth | 22.2% |
Revenue growth rate | 28.2% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 27 Sep 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2025 | 4,268 | N/A | N/A | 567 | 1 |
12/31/2024 | 3,589 | N/A | N/A | 429 | 1 |
9/30/2024 | 2,846 | 284 | -1,151 | 278 | N/A |
6/30/2024 | 2,773 | 325 | -1,021 | 306 | N/A |
3/31/2024 | 2,767 | 361 | -602 | 416 | N/A |
12/31/2023 | 2,783 | 371 | -71 | 619 | N/A |
9/30/2023 | 2,654 | 339 | 156 | 661 | N/A |
6/30/2023 | 2,619 | 363 | 18 | 562 | N/A |
3/31/2023 | 2,445 | 359 | -133 | 388 | N/A |
12/31/2022 | 2,200 | 319 | -268 | 272 | N/A |
9/30/2022 | 1,994 | 308 | -345 | 223 | N/A |
6/30/2022 | 1,813 | 263 | -191 | 279 | N/A |
3/31/2022 | 1,671 | 236 | -219 | 197 | N/A |
12/31/2021 | 1,594 | 237 | -97 | 264 | N/A |
9/30/2021 | 1,519 | 257 | -121 | 161 | N/A |
6/30/2021 | 1,344 | 237 | -127 | 104 | N/A |
3/31/2021 | 1,311 | 253 | 0 | 257 | N/A |
12/31/2020 | 1,320 | 307 | 82 | 335 | N/A |
9/30/2020 | 1,350 | 297 | N/A | N/A | N/A |
12/31/2019 | 1,511 | 270 | 149 | 281 | N/A |
12/31/2018 | 1,400 | 199 | 20 | 141 | N/A |
12/31/2017 | 925 | 56 | N/A | 81 | N/A |
12/31/2016 | 763 | 29 | N/A | 93 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if 605077's forecast earnings growth is above the savings rate (2.8%).
Earnings vs Market: Insufficient data to determine if 605077's earnings are forecast to grow faster than the CN market
High Growth Earnings: Insufficient data to determine if 605077's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 605077's revenue (28.2% per year) is forecast to grow faster than the CN market (13.8% per year).
High Growth Revenue: 605077's revenue (28.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 605077's Return on Equity is forecast to be high in 3 years time